RBC Capital analyst Conor McNamara maintained a Buy rating on Illumina (ILMN – Research Report) on January 24 and set a price target of $258.00. The company’s shares closed yesterday at $140.63.
McNamara covers the Healthcare sector, focusing on stocks such as Illumina, QuidelOrtho, and SOPHiA GENETICS. According to TipRanks, McNamara has an average return of -10.0% and a 38.81% success rate on recommended stocks.
In addition to RBC Capital, Illumina also received a Buy from Leerink Partners’s Puneet Souda in a report issued on January 9. However, on January 25, Barclays maintained a Sell rating on Illumina (NASDAQ: ILMN).
See the top stocks recommended by analysts >>
ILMN market cap is currently $22.67B and has a P/E ratio of -20.05.
Based on the recent corporate insider activity of 66 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ILMN in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Illumina (ILMN) Company Description:
Incorporated in 1998, Illumina, Inc. is a California-based company which develops, manufactures, and markets integrated systems for the analysis of genetic variation and biological function. Its products and services serve customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions. The company’s products include microarray scanners, sequencing reagents, and onsite training selector. Its services include sequencing and microarray services; proactive instrument monitoring; and instrument services, training, and consulting.
Read More on ILMN:
- Illumina price target raised to $80 from $50 at Barclays
- Concentric by Ginkgo enters into co-marketing agreement with Illumina
- Illumina sees less instrument placements in 2024 vs. 2023
- llumina sees FY24 results ‘very similar’ to FY23
- Illumina (NASDAQ:ILMN) Shines on Impressive Q4 Preliminary Numbers
